The U.S. Centers for Disease Control and Prevention has accepted its advisory panel's recommendations on vaccines for ...

The FDA and CDC are recommending a pause on the use of Ixchiq (chikungunya vaccine, live) in patients 60 years and older during an ongoing safety investigation.

The CDC began recommending Ixchiq last year for adults traveling to countries where chikungunya is common. The vaccine uses a ...

The U.S. Centers for Disease Control and Prevention accepted its advisory panel's recommendations on vaccines for chikungunya ...

The FDA and CDC recommended a pause for Ixchiq, a chikungunya vaccine, following reports of adverse events in recipients 60 ...

The U.S. government is advising that international travelers age 60 and older not get a chikungunya vaccine as it ...

The final recommendations will assist physicians in choosing appropriate vaccines ... available on the CDC's website. Both Bavarian Nordic and Valneva make vaccines for chikungunya.

"FDA and CDC will continue the evaluation ... At the time of the vaccine's approval, the FDA described chikungunya as an "emerging global health threat," with at least five million cases reported ...

Chikungunya isn't prevalent in the U.S., but travelers are being told to be cautious about getting the vaccine for the ...